EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review

Shihua Ling, Xia Dou

Acta Dermato-Venereologica · 27.05.2025 · 105 · adv43588

DOI: 10.2340/actadv.v105.43588 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Acta Dermato-Venereologica, online erschienen am 27.05.2025. Verfasst von Shihua Ling und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China; Shantou University Medical College, Shantou, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China; Shantou University Medical College, Shantou, China.
  • Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China. drdouxia@163.com.

Zitieren

APA

Ling, S., & Dou, X. (2025). Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review. Acta Dermato-Venereologica, 105, adv43588. https://doi.org/10.2340/actadv.v105.43588

Vancouver

Ling S, Dou X. Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review. Acta Dermato-Venereologica. 2025;105:adv43588. doi:10.2340/actadv.v105.43588

BibTeX
@article{Ling2025,
  author = {Ling, Shihua and Dou, Xia},
  title = {Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review},
  journal = {Acta Dermato-Venereologica},
  year = {2025},
  volume = {105},
  pages = {adv43588},
  doi = {10.2340/actadv.v105.43588}
}
Kostenlos starten →